1246298-63-4

Monophosphoryl Lipid A, or GLA-SE, is a synthetic toll-like receptor 4 agonist which enhances T-cell responses to influenza vaccine in older adults.

Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.

TLR4

[1] N QURESHI. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination.[J]. The Journal of Biological Chemistry, 1985, 260 9: 5271-5278.
[2] STACIE L LAMBERT. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.[J]. PLoS ONE, 2012: e51618. DOI: 10.1371/journal.pone.0051618
[3] MAURICIO A ARIAS. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.[J]. PLoS ONE, 2012: e41144. DOI: 10.1371/journal.pone.0041144
[4] SUSAN L BALDWIN. The importance of adjuvant formulation in the development of a tuberculosis vaccine.[J]. Journal of immunology, 2012, 188 5: 2189-2197. DOI: 10.4049/jimmunol.1102696